Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01096966 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back Pain
A Phase 2 study, sponsored by Durect.
- Completed
- Registry status
- Phase 2
- Development phase
- 263
- Enrollment target
NCT01096966 is a Phase 2 study that has completed, run by Durect. The registered enrollment target is 263 participants.
The verdict
NCT01096966, a Phase 2 study, has completed, sponsored by Durect.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 263 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of Bupivacaine TTS (Bupivacaine patch) compared to placebo in patients with chronic low back pain.
Interventions
- DRUG Placebo patch
- DRUG Bupivacaine TTS (Bupivacaine Patch)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01096966
The ClinicalTrials.gov registry entry for NCT01096966 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Durect, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo patch is the first listed.
NCT01096966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01096966 about?
NCT01096966 is a clinical study titled "Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back Pain". This study will evaluate the efficacy and safety of Bupivacaine TTS (Bupivacaine patch) compared to placebo in patients with chronic low back pain.
What is the current status of trial NCT01096966?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 263 participants. The study started on 2010-03. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01096966?
The interventions under investigation include: Placebo patch (DRUG), Bupivacaine TTS (Bupivacaine Patch) (DRUG).
Who is sponsoring clinical trial NCT01096966?
This trial is sponsored by Durect, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.